AbbVie Inc. Q2 Earnings: Margin Expansion Meets Weaker Cash Flow

AbbVie reported Q2 FY2026 revenue of $16.99B, up 10.2% from $15.42B in Q2 FY2025 and 13.3% from $15.00B in Q1 FY2026. No company guidance or consensus estimate was supplied, so the prior-year quarter is the required reference. The revenue result therefore counts as a beat against that reference and represents the clearest evidence of improved operating momentum in the quarter.

Reported EPS increased to $2.03 from $0.52 a year earlier and $0.39 in the immediately preceding quarter. Net income was $3.61B. The size of the EPS change shows a significant improvement in reported profitability, although recent quarterly history has been volatile: EPS ranged from $0.10 in Q3 FY2025 to $2.03 in the latest quarter. A single strong quarter therefore should not be treated as a normalized earnings level without additional disclosure.

Operating income reached $6.43B, producing a 37.9% operating margin. That was 6.2 percentage points above the 31.7% margin reported in Q2 FY2025 and 11.3 points above Q1 FY2026. Gross profit was $12.07B, equivalent to a 71.0% gross margin. A comparable prior-year gross margin was not disclosed in the supplied quarterly table, so it is not possible to determine whether gross margin improved year over year.

Cash generation was the main negative. Free cash flow declined to $3.11B from $4.88B in Q2 FY2025, a decrease of 36.3%. It also fell 12.6% from $3.56B in Q1 FY2026. The quarter consequently delivered much stronger EPS but weaker free cash flow, creating a notable divergence between accounting earnings and cash conversion. The filing data supplied here do not disclose enough detail to assign that decline to working capital, timing or another specific cause.

The constructive interpretation is that AbbVie’s revenue recovery is gaining breadth or intensity at the consolidated level. FY2025 revenue increased 8.6% to $61.16B from $56.33B in FY2024, and Q2 FY2026 revenue growth of 10.2% remained above that annual rate. The latest operating margin also exceeded every quarter in the supplied 12-quarter history. If that margin level proves durable, the company could generate more operating profit from each dollar of revenue than its recent annual results imply.

The less favorable interpretation is that the quarter’s reported profit did not translate into comparable cash growth. AbbVie generated $17.82B of free cash flow in FY2025, nearly unchanged from $17.83B in FY2024 despite revenue growth. Q2 FY2026 then produced another year-over-year decline. Trailing free cash flow remains substantial at $18.2B, but the pattern does not yet demonstrate operating leverage in cash terms.

That distinction matters at $254.03 per share. The stock trades at a 4.0% trailing free-cash-flow yield and 71.8x trailing GAAP EPS of $3.54. The earnings multiple is affected by the volatility visible in reported GAAP EPS, making free cash flow the more stable valuation anchor from the information provided. Even on that measure, a 4.0% yield leaves limited room for weaker cash conversion or a reversal in margins.

Balance-sheet risk also remains relevant. The latest XBRL values show $64.50B of debt, $6.57B of cash and negative equity of $5.94B. FY2025 net debt was $59.27B. AbbVie’s FY2025 ROIC of 19.4% indicates that the operating asset base generated a strong reported return, but leverage raises the consequences if revenue growth, margins or cash generation weaken. The quarter improves the operating side of the thesis without resolving the financial-risk side.

Because SageNoodle has no prior AbbVie coverage, there is no existing fair value to move. We establish an inaugural valuation using trailing free cash flow rather than GAAP EPS. The explicit starting point is the supplied $18.2B of trailing free cash flow divided by 1.771B shares, or approximately $10.28 per share. The scenarios apply different free-cash-flow multiples to that amount; they do not assume an undisclosed consensus forecast.

The bear case applies an 18.0x multiple, producing fair value of $185.00. This scenario reflects lower cash conversion, normalization of the latest 37.9% operating margin and continued balance-sheet constraints. The base case applies 24.0x trailing free cash flow for $246.70 per share. It assumes revenue momentum remains positive and margins stay above recent annual levels, but it does not capitalize Q2 EPS as a permanent run rate. The bull case applies 30.0x for $308.40, requiring sustained margin strength and a renewed increase in free cash flow.

Our base-case fair value of $246.70 is 2.9% below the current price of $254.03. Under the stated verdict rule, that makes AbbVie fairly valued because fair value is between 85% and 115% of the market price. The quarter does not justify a more aggressive multiple: operating performance improved, but free cash flow did not confirm the same degree of progress. Evidence of sustained cash-flow growth would be necessary to support the bull-case multiple.

The principal upside risk to our valuation is that Q2’s operating margin proves sustainable while free cash flow rebounds. The 37.9% operating margin was well above the 24.6% reported for FY2025. If that difference represents a durable improvement rather than quarterly timing, a valuation based on current trailing cash flow could understate future earning power. Continued double-digit revenue growth would strengthen that conclusion.

The principal downside risk is that Q2 free cash flow is the better signal. A 36.3% year-over-year decline in free cash flow despite higher revenue and EPS could indicate weaker conversion than the income statement suggests. Without a supplied earnings release explaining the movement, the cause and likely duration are not disclosed. Repetition in subsequent quarters would challenge the assumption that trailing free cash flow is sustainable.

Margin normalization is a second downside risk. Quarterly operating margin moved from 12.1% in Q3 FY2025 to 27.3% in Q4, 26.6% in Q1 FY2026 and 37.9% in Q2. That range demonstrates substantial volatility. Treating the latest quarter as representative would materially overstate value if unusual expenses, product mix or timing drove the change.

Finally, leverage reduces room for operational disappointment. Debt of $64.50B is large relative to annual free cash flow, and equity is negative. The thesis would weaken if cash generation remains flat or declines while debt does not fall. Conversely, sustained free-cash-flow growth accompanied by lower leverage would support a lower risk assessment and potentially a higher fair-value multiple.